Advanced MR imaging of gliomas: An update

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Kao, Hung Wen ^a,b   Chiang, Shih Wei ^b,c   Chung, Hsiao Wen ^b,c   Tsai, Fong Y ^d,e   Chen, Cheng Yu ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GADOLINIUM; KI 67 ANTIGEN; VASCULOTROPIN;

BLOOD BRAIN BARRIER; BRAIN BIOPSY; BRAIN BLOOD VOLUME; CANCER RECURRENCE; CANCER SURGERY; CELLULAR DISTRIBUTION; CONTRAST ENHANCEMENT; DIFFUSION KURTOSIS IMAGING; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FRACTIONAL ANISOTROPY; FUNCTIONAL NEUROIMAGING; GLIOMA; HUMAN; LABELING INDEX; MITOSIS; MOLECULAR IMAGING; NEOVASCULARIZATION (PATHOLOGY); NEUROIMAGING; NON GAUSSIAN DIFFUSION KURTOSIS IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR INVASION; TUMOR NECROSIS; BRAIN TUMOR; PATHOLOGY; VASCULARIZATION; BRAIN NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

BRAIN NEOPLASMS; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MITOSIS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84879376559     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/970586     Document Type: Review

References (107)

1. Louis D. N., Molecular pathology of malignant gliomas. Annual Review of Pathology 2006 1 97 117 2-s2.0-33645732219 10.1146/annurev.pathol.1.110304. 100043
2. Wen P. Y., Kesari S., Malignant gliomas in adults. New England Journal of Medicine 2008 359 5 492 507 2-s2.0-48249125791 10.1056/NEJMra0708126
3. Kleihues P., Ohgaki H., Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1999 1 1 44 51 2-s2.0-0032601166
4. Freije W. A., Castro-Vargas F. E., Fang Z., Horvath S., Cloughesy T., Liau L. M., Mischel P. S., Nelson S. F., Gene expression profiling of gliomas strongly predicts survival. Cancer Research 2004 64 18 6503 6510 2-s2.0-4644313275 10.1158/0008-5472.CAN-04-0452 (Pubitemid 39297907)
5. Reifenberger G., Collins V. P., Pathology and molecular genetics of astrocytic gliomas. Journal of Molecular Medicine 2004 82 10 656 670 2-s2.0-7944234916 10.1007/s00109-004-0564-x (Pubitemid 39468490)
6. Yamanaka R., Arao T., Yajima N., Tsuchiya N., Homma J., Tanaka R., Sano M., Oide A., Sekijima M., Nishio K., Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006 25 44 5994 6002 2-s2.0-33749189559 10.1038/sj.onc.1209585 (Pubitemid 44477293)
7. Figueroa M. E., Abdel-Wahab O., Lu C., Ward P. S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H. F., Tallman M. S., Sun Z., Wolniak K., Peeters J. K., Liu W., Choe S. E., Fantin V. R., Paietta E., Löwenberg B., Licht J. D., Godley L. A., Delwel R., Valk P. J. M., Thompson C. B., Levine R. L., Melnick A., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 18 6 553 567 2-s2.0-78650019179 10.1016/j.ccr.2010.11.015
8. Thon N., Eigenbrod S., Kreth S., Lutz J., Tonn J. C., Kretzschmar H., Peraud A., Kreth F. W., IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012 118 2 452 460
9. Walker C., Du Plessis D. G., Joyce K. A., Fildes D., Gee A., Haylock B., Husband D., Smith T., Broome J., Warnke P. C., Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Annals of Neurology 2005 57 6 855 865 2-s2.0-20444413007 10.1002/ana.20496 (Pubitemid 40798624)
10. Smith J. S., Perry A., Borell T. J., Lee H. K., O'Fallon J., Hosek S. M., Kimmel D., Yates A., Burger P. C., Scheithauer B. W., Jenkins R. B., Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology 2000 18 3 636 645 2-s2.0-0033951824 (Pubitemid 30078545)
11. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P. L., Burkhard C., Schüler D., Probst-Hensch N. M., Maiorka P. C., Baeza N., Pisani P., Yonekawa Y., Yasargil M. G., Lütolf U. M., Kleihues P., Genetic pathways to glioblastoma: a population-based study. Cancer Research 2004 64 19 6892 6899 2-s2.0-4944255253 10.1158/0008-5472.CAN-04-1337 (Pubitemid 39330996)
12. Rasheed B. K. A., McLendon R. E., Friedman H. S., Friedman A. H., Fuchs H. E., Bigner D. D., Bigner S. H., Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995 10 11 2243 2246 2-s2.0-0029024891
13. Nakamura M., Yang F., Fujisawa H., Yonekawa Y., Kleihues P., Ohgaki H., Loss of heterozygosity on chromosome 19 in secondary glioblastomas. Journal of Neuropathology and Experimental Neurology 2000 59 6 539 543 2-s2.0-0034084423 (Pubitemid 30368313)
14. Homma T., Fukushima T., Vaccarella S., Yonekawa Y., Di Patre P. L., Franceschi S., Ohgaki H., Correlation among pathology, genotype, and patient outcomes in glioblastoma. Journal of Neuropathology and Experimental Neurology 2006 65 9 846 854 2-s2.0-33748533494 10.1097/01.jnen.0000235118.75182.94 (Pubitemid 44371230)
15. Curran W. J. Jr., Scott C. B., Horton J., Nelson J. S., Weinstein A. S., Fischbach A. J., Chang C. H., Rotman M., Asbell S. O., Krisch R. E., Nelson D. F., Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. Journal of the National Cancer Institute 1993 85 9 704 710 2-s2.0-0027294649 (Pubitemid 23133591)
16. Prados M. D., Seiferheld W., Sandler H. M., Buckner J. C., Phillips T., Schultz C., Urtasun R., Davis R., Gutin P., Cascino T. L., Greenberg H. S., Curran W. J., Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. International Journal of Radiation Oncology Biology Physics 2004 58 4 1147 1152 2-s2.0-12144286887 10.1016/j.ijrobp.2003.08.024 (Pubitemid 38314798)
17. Cao Y., Sundgren P. C., Tsien C. I., Chenevert T. T., Junck L., Physiologic and metabolic magnetic resonance imaging in gliomas. Journal of Clinical Oncology 2006 24 8 1228 1235 2-s2.0-33644864520 10.1200/JCO.2005.04. 7233 (Pubitemid 46622025)
18. Jenkinson M. D., Plessis D. G. D., Walker C., Smith T. S., Advanced MRI in the management of adult gliomas. British Journal of Neurosurgery 2007 21 6 550 561 2-s2.0-37049025568 10.1080/02688690701642020 (Pubitemid 350249197)
19. Price S. J., The role of advanced MR imaging in understanding brain tumour pathology. British Journal of Neurosurgery 2007 21 6 562 575 2-s2.0-37049003735 10.1080/02688690701700935 (Pubitemid 350249196)
20. Gupta A., Young R. J., Karimi S., Sood S., Zhang Z., Mo Q., Gutin P. H., Holodny A. I., Lassman A. B., Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. American Journal of Neuroradiology 2011 32 7 1301 1306
21. Hu L. S., Eschbacher J. M., Dueck A. C., Heiserman J. E., Liu S., Karis J. P., Smith K. A., Shapiro W. R., Pinnaduwage D. S., Coons S. W., Nakaji P., Debbins J., Feuerstein B. G., Baxter L. C., Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. American Journal of Neuroradiology 2012 33 1 69 76
22. Noguchi K., Watanabe N., Nagayoshi T., Kanazawa T., Toyoshima S., Shimizu M., Seto H., Role of diffusion-weighted echo-planar MRI in distinguishing between brain abscess and tumour: a preliminary report. Neuroradiology 1999 41 3 171 174 2-s2.0-0032984674 10.1007/s002340050726 (Pubitemid 29126780)
23. Stadnik T. W., Chaskis C., Michotte A., Shabana W. M., Van Rompaey K., Luypaert R., Budinsky L., Jellus V., Osteaux M., Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. American Journal of Neuroradiology 2001 22 5 969 976 2-s2.0-0035039427 (Pubitemid 32436243)
24. Higano S., Yun X., Kumabe T., Watanabe M., Mugikura S., Umetsu A., Sato A., Yamada T., Takahashi S., Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006 241 3 839 846 2-s2.0-33846700422 10.1148/radiol.2413051276 (Pubitemid 46190551)
25. Sugahara T., Korogi Y., Kochi M., Ikushima I., Shigematu Y., Hirai T., Okuda T., Liang L., Ge Y., Komohara Y., Ushio Y., Takahashi M., Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. Journal of Magnetic Resonance Imaging 1999 9 1 53 60 (Pubitemid 29068231)
26. Kang Y., Choi S. H., Kim Y. J., Kim K. G., Sohn C. H., Kim J. H., Yun T. J., Chang K. H., Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology 2011 261 3 882 890
27. Mori S., Frederiksen K., Van Zijl P. C. M., Stieltjes B., Kraut M. A., Solaiyappan M., Pomper M. G., Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging. Annals of Neurology 2002 51 3 377 380 2-s2.0-0036194085 10.1002/ana.10137 (Pubitemid 34206295)
28. Price S. J., Burnet N. G., Donovan T., Green H. A. L., Peña A., Antoun N. M., Pickard J. D., Carpenter T. A., Gillard J. H., Diffusion tensor imaging of brain tumours at 3 T: a potential tool for assessing white matter tract invasion? Clinical Radiology 2003 58 6 455 462 2-s2.0-0037864158 10.1016/S0009-9260(03)00115-6 (Pubitemid 36700758)
29. Lu S., Ahn D., Johnson G., Cha S., Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. American Journal of Neuroradiology 2003 24 5 937 941 2-s2.0-0037503015 (Pubitemid 36617427)
30. Inoue T., Ogasawara K., Beppu T., Ogawa A., Kabasawa H., Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clinical Neurology and Neurosurgery 2005 107 3 174 180 2-s2.0-17044394283 10.1016/j.clineuro.2004.06.011
31. Goebell E., Paustenbach S., Vaeterlein O., Ding X. Q., Heese O., Fiehler J., Kucinski T., Hagel C., Westphal M., Zeumer H., Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging. Radiology 2006 239 1 217 222 2-s2.0-33645117181 10.1148/radiol.2383050059
32. Holodny A. I., Ollenschleger M. D., Liu W. C., Schulder M., Kalnin A. J., Identification of the corticospinal tracts achieved using blood-oxygen-level- dependent and diffusion functional MR imaging in patients with brain tumors. American Journal of Neuroradiology 2001 22 1 83 88 2-s2.0-0035143313 (Pubitemid 32105359)
33. Schulder M., Maldjian J. A., Liu W. C., Holodny A. I., Kalnin A. T., Mun I. K., Carmel P. W., Functional image-guided surgery of intracranial tumors located in or near the sensorimotor cortex. Journal of Neurosurgery 1998 89 3 412 418 2-s2.0-0031721261 (Pubitemid 28405255)
34. Jensen J. H., Helpern J. A., Ramani A., Lu H., Kaczynski K., Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging. Magnetic Resonance in Medicine 2005 53 6 1432 1440 2-s2.0-19544371362 10.1002/mrm.20508 (Pubitemid 40734665)
35. Van Cauter S., Veraart J., Sijbers J., Peeters R. R., Himmelreich U., De Keyzer F., Van Gool S. W., Van Calenbergh F., De Vleeschouwer S., Van Hecke W., Sunaert S., Gliomas: diffusion kurtosis MR imaging in grading. Radiology 2012 263 2 492 501
36. Wakimoto H., Aoyagi M., Nakayama T., Nagashima G., Yamamoto S., Tamaki M., Hirakawa K., Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996 77 2 373 380 (Pubitemid 26025528)
37. Hoshino T., Ahn D., Prados M. D., Lamborn K., Wilson C. B., Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. International Journal of Cancer 1993 53 4 550 555 2-s2.0-0027461601 (Pubitemid 23069262)
38. Mckeever P. E., Ross D. A., Strawderman M. S., Brunberg J. A., Greenberg H. S., Junck L., A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. Journal of Neuropathology and Experimental Neurology 1997 56 7 798 805 2-s2.0-0030949269 (Pubitemid 27280190)
39. Sallinen P. K., Haapasalo H. K., Visakorpi T., Helén P. T., Rantala I. S., Isola J. J., Helin H. J., Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. Journal of Pathology 1994 174 4 275 282 2-s2.0-0028725419
40. Tynninen O., Aronen H. J., Ruhala M., Paetau A., Von Boguslawski K., Salonen O., Jääskeläinen J., Paavonen T., MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Investigative Radiology 1999 34 6 427 434 2-s2.0-0032916008 10.1097/00004424- 199906000-00007 (Pubitemid 29239360)
41. Kiss R., Dewitte O., Decaestecker C., Camby I., Gordower L., Delbecque K., Pasteels J. L., Brotchi J., Salmon I., The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors. American Journal of Clinical Pathology 1997 107 3 321 331 2-s2.0-0031040544 (Pubitemid 27090237)
42. Sadeghi N., Salmon I., Decaestecker C., Levivier M., Metens T., Wikler D., Denolin V., Rorive S., Massager N., Baleriaux D., Goldman S., Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. American Journal of Neuroradiology 2007 28 3 455 461 2-s2.0-33947579576 (Pubitemid 46481882)
43. Barbarella G., Ricci R., Pirini G., Tugnoli V., Tosi M. R., Bertoluzza A., Calbucci F., Leonardi M., Trevisan C., Eusebi V., In vivo single voxel 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS. International Journal of Oncology 1998 12 2 461 468 2-s2.0-13144281702 (Pubitemid 28064877)
44. Shimizu H., Kumabe T., Shirane R., Yoshimoto T., Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. American Journal of Neuroradiology 2000 21 4 659 665 2-s2.0-0034118137 (Pubitemid 30210427)
45. Matsumura A., Isobe T., Anno I., Takano S., Kawamura H., Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study. Journal of Clinical Neuroscience 2005 12 4 416 420 2-s2.0-19744377982 10.1016/j.jocn.2004.08.008 (Pubitemid 40745226)
46. Tamiya T., Kinoshita K., Ono Y., Matsumoto K., Furuta T., Ohmoto T., Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000 42 5 333 338 2-s2.0-0034065534 (Pubitemid 30265348)
47. Mcknight T. R., Lamborn K. R., Love T. D., Berger M. S., Chang S., Dillon W. P., Bollen A., Nelson S. J., Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. Journal of Neurosurgery 2007 106 4 660 666 2-s2.0-34047202785 10.3171/jns.2007.106.4.660 (Pubitemid 46536464)
48. Guillevin R., Menuel C., Duffau H., Kujas M., Capelle L., Aubert A., Taillibert S., Idbaih A., Pallud J., Demarco G., Costalat R., Hoang-Xuan K., Chiras J., Vallée J. N., Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. Journal of Neuro-Oncology 2008 87 2 181 187 2-s2.0-41549159456 10.1007/s11060-007-9508-y
49. Castillo M., Smith J. K., Kwock L., Correlation of myo-inositol levels and grading of cerebral astrocytomas. American Journal of Neuroradiology 2000 21 9 1645 1649 2-s2.0-0033775878
50. Plate K. H., Breier G., Weich H. A., Risau W., Vascular endothelial growth factor is a potential tumour angiogenssis factor in human gliomas in vivo. Nature 1992 359 6398 845 848 2-s2.0-0026446102 10.1038/359845a0
51. Kargiotis O., Rao J. S., Kyritsis A. P., Mechanisms of angiogenesis in gliomas. Journal of Neuro-Oncology 2006 78 3 281 293 2-s2.0-33745784386 10.1007/s11060-005-9097-6 (Pubitemid 44018823)
52. Machein M. R., Plate K. H., VEGF in brain tumors. Journal of Neuro-Oncology 2000 50 1-2 109 120 2-s2.0-0034470387 10.1023/A:1006416003964 (Pubitemid 32166295)
53. Senger D. R., Van De Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F., Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer and Metastasis Reviews 1993 12 3-4 303 324 2-s2.0-0027359953 (Pubitemid 23293287)
54. Ashrafpour H., Huang N., Neligan P. C., Forrest C. R., Addison P. D., Moses M. A., Levine R. H., Pang C. Y., Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. American Journal of Physiology 2004 286 3 H946 H954 2-s2.0-1342304203 (Pubitemid 38248608)
55. Ku D. D., Zaleski J. K., Liu S., Brock T. A., Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. American Journal of Physiology 1993 265 2, part 2 H586 H592 2-s2.0-0027217832 (Pubitemid 23273595)
56. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 219 4587 983 985 2-s2.0-0021111648
57. Vajkoczy P., Menger M. D., Vascular microenvironment in gliomas. Cancer Treatment and Research 2004 117 249 262 2-s2.0-2342422295
58. Vick N. A., Bigner D. D., Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. Journal of the Neurological Sciences 1972 17 1 29 39 2-s2.0-0015400075
59. Birner P., Piribauer M., Fischer I., Gatterbauer B., Marosi C., Ambros P. F., Ambros I. M., Bredel M., Oberhuber G., Rössler K., Budka H., Harris A. L., Hainfellner J. A., Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathology 2003 13 2 133 143 2-s2.0-0344837730 (Pubitemid 36460814)
60. Østergaard L., Principles of cerebral perfusion imaging by bolus tracking. Journal of Magnetic Resonance Imaging 2005 22 6 710 717 2-s2.0-28444463228 10.1002/jmri.20460 (Pubitemid 41741235)
61. Aronen H. J., Pardo F. S., Kennedy D. N., Belliveau J. W., Packard S. D., Hsu D. W., Hochberg F. H., Fischman A. J., Rosen B. R., High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clinical Cancer Research 2000 6 6 2189 2200 2-s2.0-0034131067 (Pubitemid 30399184)
62. Dean B. L., Lee C., Kirsch J. E., Runge V. M., Dempsey R. M., Pettigrew L. C., Cerebral hemodynamics and cerebral blood volume: MR assessment using gadolinium contrast agents and T1-weighted turbo-FLASH imaging. American Journal of Neuroradiology 1992 13 1 39 48 2-s2.0-0026556271
63. Hackländer T., Reichenbach J. R., Hofer M., Mödder U., Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. American Journal of Neuroradiology 1996 17 5 821 830 2-s2.0-0030000382 (Pubitemid 26149083)
64. Boxerman J. L., Schmainda K. M., Weisskoff R. M., Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. American Journal of Neuroradiology 2006 27 4 859 867 2-s2.0-33748084051 (Pubitemid 44897737)
65. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330 (Pubitemid 40349501)
66. Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M. J., Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet Oncology 2008 9 5 453 461 2-s2.0-42649106522 10.1016/S1470-2045(08)70125-6 (Pubitemid 351597795)
67. Brandes A. A., Franceschi E., Tosoni A., Blatt V., Pession A., Tallini G., Bertorelle R., Bartolini S., Calbucci F., Andreoli A., Frezza G., Leonardi M., Spagnolli F., Ermani M., MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of Clinical Oncology 2008 26 13 2192 2197 2-s2.0-43749094544 10.1200/JCO.2007.14.8163
68. Mangla R., Singh G., Ziegelitz D., Milano M. T., Korones D. N., Zhong J., Ekholm S. E., Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010 256 2 575 584 2-s2.0-77955128785 10.1148/radiol.10091440
69. Sugahara T., Korogi Y., Tomiguchi S., Shigematsu Y., Ikushima I., Kira T., Liang L., Ushio Y., Takahashi M., Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. American Journal of Neuroradiology 2000 21 5 901 909 2-s2.0-0034064281 (Pubitemid 30262837)
70. Zhu X. P., Li K. L., Kamaly-Asl I. D., Checkley D. R., Tessier J. J., Waterton J. C., Jackson A., Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2 contrast-enhanced dynamic MR imaging. Journal of Magnetic Resonance Imaging 2000 11 6 575 585 (Pubitemid 30350299)
71. Li K. L., Zhu X. P., Checkley D. R., Tessier J. J. L., Hillier V. F., Waterton J. C., Jackson A., Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. British Journal of Radiology 2003 76 901 39 50 2-s2.0-0037280345 10.1259/bjr/31662734 (Pubitemid 36236298)
72. Roberts H. C., Roberts T. P. L., Brasch R. C., Dillon W. P., Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. American Journal of Neuroradiology 2000 21 5 891 899 2-s2.0-0034060928 (Pubitemid 30262836)
73. Provenzale J. M., Wang G. R., Brenner T., Petrella J. R., Sorensen A. G., Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. American Journal of Roentgenology 2002 178 3 711 716 2-s2.0-0036179912 (Pubitemid 34178155)
74. Mills S. J., Patankar T. A., Haroon H. A., Balériaux D., Swindell R., Jackson A., Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? American Journal of Neuroradiology 2006 27 4 853 858 2-s2.0-33748051095 (Pubitemid 44897736)
75. Ding B., Ling H. W., Chen K. M., Jiang H., Zhu Y. B., Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology 2006 48 10 773 781 2-s2.0-33749339281 10.1007/s00234-006-0120-1 (Pubitemid 44490055)
76. Ellika S. K., Jain R., Patel S. C., Scarpace L., Schultz L. R., Rock J. P., Mikkelsen T., Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. American Journal of Neuroradiology 2007 28 10 1981 1987 2-s2.0-36448938275 10.3174/ajnr.A0688 (Pubitemid 350174746)
77. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases. Nature 2000 407 6801 249 257 2-s2.0-0034648765 10.1038/35025220
78. Kazazi-Hyseni F., Beijnen J. H., Schellens J. H. M., Bevacizumab. Oncologist 2010 15 8 819 825 2-s2.0-77956855572 10.1634/theoncologist.2009-0317
79. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004 3 5 391 400 2-s2.0-2442621619 (Pubitemid 38618122)
80. Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 1997 57 20 4593 4599 2-s2.0-0030856731 (Pubitemid 27441066)
81. Ananthnarayan S., Bahng J., Roring J., Nghiemphu P., Lai A., Cloughesy T., Pope W. B., Time course of imaging changes of GBM during extended bevacizumab treatment. Journal of Neuro-Oncology 2008 88 3 339 347 2-s2.0-44649095050 10.1007/s11060-008-9573-x
82. Norden A. D., Young G. S., Setayesh K., Muzikansky A., Klufas R., Ross G. L., Ciampa A. S., Ebbeling L. G., Levy B., Drappatz J., Kesari S., Wen P. Y., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008 70 10 779 787 2-s2.0-41649112610 10.1212/01.wnl.0000304121.57857.38
83. Wen P. Y., Macdonald D. R., Reardon D. A., Cloughesy T. F., Sorensen A. G., Galanis E., DeGroot J., Wick W., Gilbert M. R., Lassman A. B., Tsien C., Mikkelsen T., Wong E. T., Chamberlain M. C., Stupp R., Lamborn K. R., Vogelbaum M. A., Van Den Bent M. J., Chang S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology 2010 28 11 1963 1972 2-s2.0-77951625266 10.1200/JCO.2009.26.3541
84. Haacke E. M., Xu Y., Cheng Y. C. N., Reichenbach J. R., Susceptibility weighted imaging (SWI). Magnetic Resonance in Medicine 2004 52 3 612 618 2-s2.0-4243162030 10.1002/mrm.20198 (Pubitemid 39108975)
85. Rauscher A., Sedlacik J., Barth M., Mentzel H. J., Reichenbach J. R., Magnetic susceptibility-weighted MR phase imaging of the human brain. American Journal of Neuroradiology 2005 26 4 736 742 2-s2.0-30544440727 (Pubitemid 43079761)
86. Park S. M., Kim H. S., Jahng G. H., Ryu C. W., Kim S. Y., Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T. British Journal of Radiology 2010 83 990 466 475 2-s2.0-77952896067 10.1259/bjr/34304111
87. Christoforidis G. A., Yang M., Abduljalil A., Chaudhury A. R., Newton H. B., McGregor J. M., Epstein C. R., Yuh W. T., Watson S., Robitaille P. M., "Tumoral pseudoblush" identified within gliomas at high-spatial-resolution ultrahigh-field-strength gradient-echo MR imaging corresponds to microvascularity at stereotactic biopsy. Radiology 2012 264 1 210 217
88. Grabner G., Nobauer I., Elandt K., Kronnerwetter C., Woehrer A., Marosi C., Prayer D., Trattnig S., Preusser M., Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magnetic Resonance Imaging 2012 30 1 139 147
89. De Backer M. E., Nabuurs R. J. A., Van Buchem M. A., Van Der Weerd L., MR-based molecular imaging of the brain: the next frontier. American Journal of Neuroradiology 2010 31 9 1577 1583 2-s2.0-77958597161 10.3174/ajnr.A2264
90. Tomanek B., Iqbal U., Blasiak B., Abulrob A., Albaghdadi H., Matyas J. R., Ponjevic D., Sutherland G. R., Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro-Oncology 2012 14 1 53 63
91. He T., Smith N., Saunders D., Doblas S., Watanabe Y., Hoyle J., Silasi-Mansat R., Lupu F., Lerner M., Brackett D. J., Towner R. A., Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. Journal of Cellular and Molecular Medicine 2011 15 4 837 849 2-s2.0-79955675257 10.1111/j.1582-4934.2010.01091.x
92. Herholz K., Heindel W., Luyten P. R., DenHollander J. A., Pietrzyk U., Voges J., Kugel H., Friedmann G., Heiss W. D., In vivo imaging of glucose consumption and lactate concentration in human gliomas. Annals of Neurology 1992 31 3 319 327 2-s2.0-0026544671
93. Alger J. R., Frank J. A., Bizzi A., Fulham M. J., DeSouza B. X., Duhaney M. O., Inscoe S. W., Black J. L., Van Zijl P. C. M., Moonen C. T. W., Di Chiro G., Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990 177 3 633 641 2-s2.0-0025221242
94. Rémy C., Fouilhé N., Barba I., Sam-Laï E., Lahrech H., Cucurella M. G., Izquierdo M., Moreno A., Ziegler A., Massarelli R., Décorps M., Arús C., Evidence that mobile lipids detected in rat brain glioma by 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Research 1997 57 3 407 414 2-s2.0-1842288617 (Pubitemid 27081656)
95. Zonari P., Baraldi P., Crisi G., Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology 2007 49 10 795 803 2-s2.0-34848833884 10.1007/s00234-007-0253-x (Pubitemid 47497767)
96. Meyerand M. E., Pipas J. M., Mamourian A., Tosteson T. D., Dunn J. F., Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. American Journal of Neuroradiology 1999 20 1 117 123 2-s2.0-0033501045 (Pubitemid 30417680)
97. Yang D., Korogi Y., Sugahara T., Kitajima M., Shigematsu Y., Liang L., Ushio Y., Takahashi M., Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002 44 8 656 666 2-s2.0-0036935171 10.1007/s00234-002-0816-9 (Pubitemid 36075928)
98. Li X., Vigneron D. B., Cha S., Graves E. E., Crawford F., Chang S. M., Nelson S. J., Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. American Journal of Neuroradiology 2005 26 4 760 769 2-s2.0-27944442948 (Pubitemid 43079765)
99. Kumar A. J., Leeds N. E., Fuller G. N., Van Tassel P., Maor M. H., Sawaya R. E., Levin V. A., Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000 217 2 377 384 2-s2.0-0033735455
100. Mullins M. E., Barest G. D., Schaefer P. W., Hochberg F. H., Gonzalez R. G., Lev M. H., Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. American Journal of Neuroradiology 2005 26 8 1967 1972 2-s2.0-32944475186
101. Nakajima T., Kumabe T., Kanamori M., Saito R., Tashiro M., Watanabe M., Tominaga T., Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurologia Medico-Chirurgica 2009 49 9 394 401 2-s2.0-70350046539 10.2176/nmc.49.394
102. Barajas R. F. Jr., Chang J. S., Segal M. R., Parsa A. T., McDermott M. W., Berger M. S., Cha S., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009 253 2 486 496 2-s2.0-76749097367 10.1148/radiol.2532090007
103. Larsen V. A., Simonsen H. J., Law I., Larsson H. B., Hansen A. E., Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 2013 55 3 361 369
104. Hakyemez B., Erdogan C., Yildirim N., Parlak M., Glioblastoma multiforme with atypical diffusion-weighted MR findings. British Journal of Radiology 2005 78 935 989 992 2-s2.0-28044454142 10.1259/bjr/12830378 (Pubitemid 41684025)
105. Batra A., Tripathi R. P., Atypical diffusion-weighted magnetic resonance findings in glioblastoma multiforme. Australasian Radiology 2004 48 3 388 391 2-s2.0-7044222594 10.1111/j.0004-8461.2004.01324.x (Pubitemid 39421086)
106. Chiang I. C., Hsieh T. J., Chiu M. L., Liu G. C., Kuo Y. T., Lin W. C., Distinction between pyogenic brain abscess and necrotic brain tumour using 3-tesla MR spectroscopy, diffusion and perfusion imaging. British Journal of Radiology 2009 82 982 813 820 2-s2.0-70349288406 10.1259/bjr/90100265
107. Toh C. H., Wei K. C., Chang C. N., Hsu P. W., Wong H. F., Ng S. H., Castillo M., Lin C. P., Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging. American Journal of Neuroradiology 2012 33 8 1534 1538